3
Announcements
Trials
Browse
Landscape
Phase
Phase 4
1
Phase 2
1
Phase 1
1
Status
Unknown
3
Sponsor Class
OTHER
3
Study Type
Interventional
3
Sponsor
Cancer Type
Classical hematology
12
Plasma cell
3
Gastrointestinal
3
Tumor-Agnostic
2
Thoracic
2
Genitourinary
2
Sarcoma
1
Other hematologic neoplasm
1
Myeloid
1
Lymphoid
1
Gynecologic
1
CNS
1
Breast
1
Conditions
Colonic Neoplasms
2
Carcinoma, Hepatocellular
2
Venous Thrombosis
1
Thrombosis
1
Thromboembolism
1
Stomach Neoplasms
1
Prostatic Neoplasms
1
Pancreatic Neoplasms
1
Neoplasms
1
Lung Neoplasms
1
Inflammation
1
Immune System Diseases
1
Gastrointestinal Stromal Tumors
1
Gallbladder Neoplasms
1
Esophageal Neoplasms
1
Duodenal Neoplasms
1
Cholangiocarcinoma
1
Cardiovascular Diseases
1
Breast Neoplasms
1
Biliary Tract Neoplasms
1
Interventions
Oxaliplatin
1004
Fluorouracil
800
Capecitabine
764
Gemcitabine
650
Leucovorin
559
Irinotecan
537
Bevacizumab
513
Radiotherapy
460
Cisplatin
440
Drug Therapy
298
Cetuximab
280
Surgical Procedures, Operative
229
Paclitaxel
228
S 1 (combination)
217
pembrolizumab
205
Docetaxel
199
130-nm albumin-bound paclitaxel
196
Nivolumab
193
sintilimab
191
Radiosurgery
190
lenvatinib
180
Folfox protocol
179
Sorafenib
178
Albumin-Bound Paclitaxel
173
apatinib
170
tislelizumab
161
camrelizumab
160
Neoadjuvant Therapy
158
Blood Specimen Collection
154
durvalumab
148
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
3 trials
Recent
Start date
Enrollment
OTHER
×
Rivaroxaban
×
Gastrointestinal
×
Clear all
NCT06065592
2023-10-06
CAT_PB
Lebanese University
Phase 1
Unknown
500 enrolled
NCT05303818
2022-03-31
Ésquilo
Hospital do Servidor Publico Estadual
Phase 4
Unknown
68 enrolled
NCT03139487
2020-01-06
PRIORITY
Asan Medical Center
Phase 2
Unknown
176 enrolled